key: cord-0722224-e544gdzx
authors: Wiencek, J. R.; Head, C. L.; Sifri, C. D.; Parsons, A. S.
title: Clinical Ordering Practices of the SARS-CoV-2 Antibody Test at a Large Academic Medical Center
date: 2020-07-14
journal: nan
DOI: 10.1101/2020.07.12.20152165
sha: 7184a0bc4979a690b4c199c95ec6de641a054429
doc_id: 722224
cord_uid: e544gdzx

Background: The novel severe acute respiratory coronavirus 2 (SARS-CoV-2) that causes COVID-19 originated in December 2019 and has now infected over 3 million people in the United States. In Spring of 2020, private laboratories and some hospitals began antibody testing despite lacking evidence-based guidance. Objective: To describe clinician-described indications for SARS-CoV-2 antibody testing, including cost implications, immediately following testing availability. Design: Retrospective chart review of patients who received antibody testing from May 14, 2020 to June 15, 2020. Setting: A large academic medical center, one of the first in the US to provide antibody testing capability to individual clinicians. Patients: 447 consecutive patients who received SARS-CoV-2 antibody testing. Measurements: Clinician-described indications for SARS-CoV-2 antibody testing, cost implications, and comparison with current expert-based guidance from the IDSA and CDC. Results: Of 444 individual antibody test results meeting inclusion criteria, the two most commonly described indications for ordering the antibody test, apart from public health epidemiology studies (n=223), were for patients with a now resolved COVID-19 compatible illness (n=105) with no previous molecular testing and in asymptomatic patients believed to have had a past exposure or contact with a person with COVID-19 compatible illness (n=60). The rate of positive SARS-CoV-2 antibody testing among those indications consistent with current IDSA and CDC guidance was 17% compared with 5% (p<0.0001) among those indications inconsistent with current IDSA and CDC guidance. Total cost estimates ranged from $57,720 to $97,680, of which 42% was for testing inconsistent with current expert-based guidance. Limitations: The duration of antibody response following infection is unclear and asymptomatic individuals may not develop a positive antibody response. Conclusions: Our findings demonstrate a dissociation between clinician described indications for testing and expert-based guidance and a significantly different rate of positive testing between these two groups. Clinical curiosity and patient preference appear to have played a significant role in testing decisions and substantially contributed to testing costs.

Coronavirus disease 19 is an international crisis that continues to influence every facet of human life. The novel severe acute respiratory coronavirus 2 (SARS-CoV-2) that causes COVID- 19 Over 200 antibody tests (e.g., IgG, IgM and IgG/IgM combo) flooded the market and were distributed without being properly vetted through the typical Food and Drug Administration (FDA) process. (6) This led to general concerns about various antibody test accuracy, prompting the FDA to modify its stance about data review and to now require all in vitro diagnostic test manufacturers to submit their tests through the FDA Emergency Use Authorization pathway. (7) The utility and limitations of the antibody test have been at the forefront of discussions in the medical and lay communities. (8, 9) , (10)

The clinical and public health necessity for ordering the SARS-CoV-2 antibody test remains poorly described. To this point, the test has primarily been used in epidemiological studies to determine disease burden. (11, 12) For instance, a recent analysis of SARS-CoV-2 antibody test results from nearly 12,000 serum samples collected as part of routine or sick care (but unrelated to suggested that the COVID-19 burden may be more than ten times greater than previously thought. (12) Yet, the antibody response in infected patients remains largely unknown, and the clinical value of antibody testing has not been fully demonstrated. (13, 14) Given the current lack of evidence-based guidance, guidelines from the Infectious Diseases Society of America (IDSA) based on expert opinion focused on four situations where the detection of antibodies could be helpful such as public health surveillance and identification of convalescent plasma donors.(15) Similarly, the Centers for Disease Control and Prevention (CDC) released interim guidance that urged healthcare professionals to not use antibody tests as a means to diagnosis a patient with COVID-19.(16) Despite lacking evidencebased guidance, private laboratories and some hospitals began antibody testing in early spring of 2020. (17) Widespread availability of the SARS-CoV-2 antibody test with limited guidance on appropriate testing indications within the clinical environment may lead to significant healthcare waste as the pandemic continues. Excessive laboratory testing is a known driver of healthcare waste and can negatively impact clinical outcomes. (18) The SARS-CoV-2 antibody test is currently estimated to cost between $30 and $50, a price that increases to between $120 and $175 dollars when administration costs are included. (19) America's Health Insurance Plans (AHIP) estimates that widespread antibody testing could cost the US between $5 and $19 billion. (19) Yet, incomplete evidence on how the test currently is or should be used limits an accurate estimate of cost in a time when the resource implications of widespread antibody testing are of upmost importance.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 14, 2020. Herein, we describe the indications for SARS-CoV-2 antibody testing immediately following testing availability at a large academic medical center. As one of the first medical centers in the US to provide antibody testing capability to individual clinicians, we hope our experience serves as a guide for clinicians at other medical centers utilizing SARS-CoV-2 antibody testing and informs policy-makers aiming to define testing indications that promote high-value care to patients and the public at large.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 14, 2020. . https://doi.org/10.1101/2020.07.12.20152165 doi: medRxiv preprint

The University of Virginia Health System (UVAHS) began SARS-CoV-2 antibody testing on May 14, 2020. Antibody testing was performed in our central clinical laboratory on the Abbott Architect i2000 analyzer utilizing the EUA SARS-CoV-2 IgG antibody immunoassay. Before any patients were tested, the SARS-CoV-2 IgG antibody test was validated similarly as previously described. 20 We conducted a retrospective chart review of patients who received antibody testing at UVAHS from May 14, 2020 to June 15, 2020 to identify the indications for testing as described by the ordering clinician in the electronic medical record (EMR). Chart review was performed under a protocol that was approved by the University of Virginia Institutional Review Board (IRB-HSR #13310).

To identify patients to be included in the retrospective chart review, we developed an automated report that identified SARS-CoV-2 antibody test orders within the EMR. This report included fields for order identification number, date of order, ordering clinician, patient location, laboratory procedure number, medical record number (MRN), test result, result time, and result status. Prisoners, patients tested for test validation, and patients with charts that were locked from outside review due to privacy concerns were excluded.

When available, the patient MRN was used to access and review patient charts within the EMR to identify the indication used by the clinician to order the SARS-CoV-2 antibody test. To do this, we reviewed recent patient encounter documentation including patient charts, MyChart communications, and laboratory orders. We looked for documentation by the ordering clinician indicating the purpose for ordering the SARS-CoV-2 antibody test reviewing as far back as January 1, 2020. If there was not enough information available for the reviewer to identify the indication the ordering clinician was using, then a 'no indication provided' label was assigned to that test.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 14, 2020. . https://doi.org/10.1101/2020.07.12.20152165 doi: medRxiv preprint Beyond the indication used for antibody testing, we collected additional information including age, sex, timing for onset of symptoms as reported by the patient, as well as any records of COVID-19 viral RT-PCR tests ordered prior to the SARS-CoV-2 antibody test with the associated date and result of the test. Due to the retrospective focus of the study, we did not include RT-PCR tests in our data that occurred on dates after the SARS-CoV-2 antibody test.

A subset of the laboratory orders included in the automated report did not have an associated MRN, preventing us from performing chart reviews to identify the indication for antibody testing. However, using the ordering clinician information included in the report, we were able to identify the indication for testing without reviewing the chart. Within our study, there were two scenarios that required this approach. The first was a small subset of SARS-CoV-2 tests ordered for efficacy evaluation of this newly developed antibody test. These orders were excluded from our data set (n=3). The second scenario was related to epidemiologic studies evaluating the prevalence of COVID-19 by public health entities (n=222). This second group of tests was included in our analysis as epidemiologic studies fall within the current guidelines for ordering antibody testing.

All data was de-identified and collected into Microsoft Excel. The range, mean, standard deviation, and median were determined. The unpaired t test, assuming equal variance with an alpha value of 0.05, was used to compare means of two unmatched groups, those testing indications consistent with IDSA or CDC guidance and those testing indications inconsistent with such guidance.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 14, 2020. . https://doi.org/10.1101/2020.07.12.20152165 doi: medRxiv preprint Current IDSA and CDC expert-based recommendations for antibody testing were reviewed to formulate a list of possible testing indications (Table 1) . Indications noted in the EMR that were not included in the CDC or IDSA guidelines were added to the list (Table 1) .

There were 11 indications in total. Indications A, E, H, and K were provided by the IDSA and indications A, E, H, and F were provided by the CDC. Recommendations B, C, D, G, I, J were based on chart review. Once a clinician-described indication was identified through chart review, the indication was matched to the list of testing indications developed by our team. The positive antibody result rate was then calculated for these patients.

An estimated cost analysis of the SARS-CoV-2 antibody test was performed utilizing all reviewed tests between May 14, 2020 to June 15, 2020. Test and test administration (i.e., office visit) cost data from the AHIP were used to determine total costs in both low and high cost situations ( Table 2) . (19) This information was further used to determine the breakdown costs associated with antibody testing within or outside current expert-based guidance.

We reviewed a total of 449 SARS-CoV-2 antibody tests collected for 447 patients over a one month time period. Five patients were excluded. Half of the remaining patients (n=220) were stratified by age and sex. Males (n=93) and females (n=127) were further separated into five distinct age groups, (0-20, 21-40 41-60, 61-80, and >80 years). The age brackets from 41-60 and 61-80 contained the most antibody tests for females (n=48) and males (n=35), respectively. Race and ethnicity information were not collected for this study as these variables were often inconsistent or missing in the EMR. The remaining (n=222) patients were associated with public . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 14, 2020. . https://doi.org/10.1101/2020.07.12.20152165 doi: medRxiv preprint health epidemiology studies and the EMR did not contain any demographic or additional patient information.

All patients were separated into distinct testing indications. This allowed nine separate categories for ordering indications for the SARS-CoV-2 antibody test and two additional groupings broken down as "other" or "no indication provided" (Figure 1 ). Each ordering indication was further classified by antibody test result and positive result rate as well as molecular test information, when available ( Table 1 ). The two most commonly described indications for ordering the antibody test were epidemiologic studies (n=223, 50%) and patients who have resolved COVID-19 compatible illness (n=105, 24%) but never had a molecular test.

The highest percentage positive result rate (80%) was to identify convalescent plasma donors.

No testing was done on patients to determine vaccine response (i.e., indication K), owing to the fact that vaccines to the SARS-CoV-2 virus are not currently available. Overall, the rate of positive SARS-CoV-2 antibody testing among all indications ranged from 0 to 80% with a median of 5%. Notably, when testing for epidemiological studies was removed, the rate of positive SARS-CoV-2 antibody testing among those indications consistent with current IDSA and CDC guidance was 17%. In comparison, the rate of positive SARS-CoV-2 antibody testing among those indications inconsistent with current IDSA and CDC guidance was 5% (p<0.0001). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 14, 2020. . https://doi.org/10.1101/2020.07.12.20152165 doi: medRxiv preprint Total cost estimates for all tests performed during the first month of testing ranged from $57,720 to $97,680 ( Table 2 ). The tests were broken up into segments by the indications used to order the test. Out of these total costs, $24,180 to $40,920, or approximately 42%, were from testing inconsistent with current expert-based guidance. Cost per positive tests were also identified in each segment. The relationship between each testing segment's low-cost per positive test estimate and share of testing was represented in a bubble graph (Figure 3 ). The size of each bubble was proportional to a segment's positive result rate. The lowest cost per positive test ($758.33 to $1,283.33) was seen when clinician ordering practices were indicated by current expert-based guidance, excluding epidemiologic study data. Though testing consistent with current expert-based guidance, excluding epidemiologic study data, had the lowest cost per positive test; it represented the lowest share of testing (8%). Epidemiologic study had the highest cost per positive test ($7,247.50) and was the indication for half of all testing (50%).

Apart from public health epidemiology studies of disease prevalence, the most common reason for a clinician to order SARS-CoV-2 antibody testing was to determine presumed immunity in patients with resolved COVID-19 compatible illness. These patients never received SARS-CoV-2 RT-PCR testing at the time of illness. The second most common reason for a clinician to order SARS-CoV-2 antibody testing was to determine presumed immunity in asymptomatic patients believed to have had a past exposure or contact with a person with COVID-19 compatible illness. Neither of these commonly documented indications are consistent with current expert-based guidance from the IDSA or CDC. Because the rate of positive SARS-CoV-2 antibody testing among those indications inconsistent with current IDSA and CDC . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 14, 2020. . https://doi.org/10.1101/2020.07.12.20152165 doi: medRxiv preprint guidance was significantly lower than the positive rate among expert-backed indications, such inconsistent testing indications are unlikely to change management decisions or be of much clinical value. The prevalence of these inconsistent testing indications suggests that clinical curiosity and patient preference played a large role in initial testing decisions.

The next most commonly identified indication for SARS-CoV-2 antibody testing was detection of RT-PCR negative cases, especially for patients who presented late in a course of illness and potentially have a viral load below the detection limit of RT-PCR assays or when lower respiratory tract sampling was not possible. This was followed by testing to help establish a diagnosis when patients presented with late complications of COVID-19 illness and testing to identify convalescent plasma donors. All three are indications consistent with expert-based guidance from the IDSA or CDC. This was followed by an indication of supporting a diagnosis of COVID-19 in a currently symptomatic patient in the absence of RT-PCR testing and to determine immune status (e.g. return to work, school use) outside of epidemiologic investigation. This reason for testing is inconsistent with the indications described in this study; whether it represent a valid and clinically meaningful use of the SARS-CoV-2 antibody test remains to be determined.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 14, 2020. . https://doi.org/10.1101/2020.07.12.20152165 doi: medRxiv preprint Finally, we assessed total cost estimates for each testing indication and cost per positive test. "Runaway costs" for the COVID-19 pandemic have been a major concern for the global community -with laboratory testing a key factor. (26) (27) (28) In this study, clinical testing consistent with current expert-based guidance had the lowest cost per positive test. Yet, almost half of the total costs were due to testing indications inconsistent with current expert-based guidance. If testing were to continue at the same rate for one year, these inconsistent testing indications would account for almost $500,000 in our hospital. Fortunately, stewardship of laboratory testing is not a new concept. (18, 29) Well-designed and carefully thought-out testing strategies have is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 14, 2020. . https://doi.org/10.1101/2020.07.12.20152165 doi: medRxiv preprint Abbott Architect SARS-CoV-2 IgG antibody test in this study provides stronger assurance than previously describe studies. (32, 33) In summary, this investigation identified clinician-documented indications for SARS-CoV-2 antibody testing immediately following testing availability. To our knowledge, we are the first to describe these testing indications from the standpoint of the ordering clinician during the COVID-19 pandemic. Our findings demonstrate a dissociation between clinician described indications for testing and expert-based guidance and a significantly different rate of positive testing between these two groups. Clinical curiosity and patient request appear to have played a significant role in testing decisions. Perhaps this should be expected given the lack of established clinical testing guidelines and the inherent fear and uncertainty driven by the global COVID-19 pandemic. However, without evidence-based guidance, further expansion of SARS-CoV-2 antibody testing availability for clinical purposes may lead to higher healthcare costs with unclear benefit.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 14, 2020. . https://doi.org/10.1101/2020.07.12.20152165 doi: medRxiv preprint Tables: Table 1 . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 14, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 14, 2020. . https://doi.org/10.1101/2020.07.12.20152165 doi: medRxiv preprint scenarios of each segment were calculated (line 8). This was done by dividing the total cost of testing by the number of positive test results in each segment. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 14, 2020. . https://doi.org/10.1101/2020.07.12.20152165 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 14, 2020. 

WHO Director-General's opening remarks at the media briefing on COVID-19 -11

The socioeconomic implications of the coronavirus pandemic (COVID-19): A review

Johns Hopkins Coronavirus Resource Center

Report from the American Society for Microbiology COVID-19 International Summit

Real-time RT-PCR in COVID-19 detection: issues affecting the results

FDA Cracks Down On Antibody Tests For Coronavirus

Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised)

Food and Drug Administration. FDA

Seen as Key to Reopening Country, Does Not Yet Deliver -The New York Times

Screening the general population for SARS CoV-2 virus and COVID-19 antibodies: a counter-argument

Labs urge CDC to change COVID-19 antibody test guidelines

Antibody Testing for COVID-19Can It Be Used as a Screening Tool in Areas With Low Prevalence?

Centers for Disease Control and Prevention

Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression. Emerg Microbes Infect

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

CDC. Information for Laboratories about Coronavirus

The Promise and Peril of Antibody Testing for COVID-19

Evidence-Based Guidelines to Eliminate Repetitive Laboratory Testing

New Study: COVID-19 Testing Costs Could Reach $25 Billion a Year for Diagnostic, $19 Billion a Year for Antibody

Antibody Testing for COVID-19: What It Tells Us and What It Doesn't | Coronavirus (COVID-19) Information for Employees and Patients

Rapid roll out of SARS-CoV-2 antibody testing-a concern

Clinical Performance of Two SARS-CoV-2 Serologic Assays

Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in

Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infection

Medically Necessary

Families First Coronavirus Response Act

The CARES Act Works for All Americans | U.S. Department of the Treasury

Transforming Laboratory Utilization Review into Laboratory Stewardship: Guidelines by the PLUGS National Committee for Laboratory Stewardship

An overview of clinical decision support systems: benefits, risks, and strategies for success. Npj Digit Med

Learning about missing data mechanisms in electronic health records-based research: a survey-based approach

SARS-CoV-2 Serology: Much Hype, Little Data